Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

22 results about "Cerebral thrombosis" patented technology

Automated acupuncture and moxibustion robot

This paper presents a medical device for treating traumatic brain injury and cerebral thrombosis through electroacupuncture. The device includes a 6-DOF (degree of freedom) mechanical arm, a multifunctional tool tip, an MRI helmet suitable for acupuncture, and magnetic resonance imaging (MRI). The acupuncture robot can insert needles and automatically manipulate specific needles by rotating or vibrating them within a specific frequency range, and can enhance the effect by applying electrical stimulation.
Owner:FUNGLYN INC

Application of penicillin tenuiplicatum in preparation of product for preventing or treating ischemic encephalopathy

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.
Owner:QINGDAO UNIV

Drug component for preventing and treating sequelae of cerebral thrombosis, preparation method and application thereof

ActiveCN116870023BOrganic active ingredientsNucleic acid vectorSequelaCerebral thrombosis
This application relates to the technical field of exosome preparation, specifically disclosing a pharmaceutical component for the prevention and treatment of sequelae of cerebral thrombosis, its preparation method, and its application. The pharmaceutical component comprises Exo-miR-17-92 and Exo-miR-30d-5p; it is obtained by secretion from mesenchymal stem cells capable of simultaneously overexpressing the genes miR-17-92 and miR-30d-5p; the sequence of the gene miR-17-92 is shown in SEQ ID NO:1, and the sequence of the gene miR-30d-5p is shown in SEQ ID NO:2. The pharmaceutical component of this application, comprising Exo-miR-17-92 and Exo-miR-30d-5p, exerts a significant and excellent therapeutic effect on sequelae of cerebral thrombosis through the synergistic effect of their expression products.
Owner:GUANGZHOU FOUR LEAF CLOVER HEALTHTECH CO LTD

Traditional Chinese medicine pellet preparation for promoting blood circulation and dredging collaterals and preparation method of traditional Chinese medicine pellet preparation

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine pellet preparation for promoting blood circulation and dredging channels and a preparation method thereof. The pellet preparation is prepared from astragalus membranaceus, salvia miltiorrhiza, American ginseng, angelica sinensis, safflower carthamus, peach kernels, radix paeoniae rubra, leeches, earthworms, sappan wood, ground beetles, dandelions, golden cypress, rhizoma dioscoreae nipponicae, mulberry twigs, radix achyranthis bidentatae, eucommia ulmoides and gastrodia elata as raw materials and starch, lactose and microcrystalline cellulose as auxiliary materials. The pellet preparation is exact in curative effect and less in toxic and side effects, has the effects of reinforcing qi and nourishing yin, extinguishing wind and eliminating evil, and promoting blood circulation to remove meridian obstruction, and is used for treating sequelae of cerebral thrombosis, cerebral infarction and cerebral hemorrhage.
Owner:LIANGS TRADITIONAL CHINESE MEDICINE CLINIC IN CHUANYING DISTRICT JILIN CITY

Syringic acid as well as preparation, pharmaceutical composition and medical application thereof

The invention provides syringic acid as well as preparation, a pharmaceutical composition and medical application thereof. The purity of the syringic acid is 95% or above, and the syringic acid can be extracted from motherwort. The syringic acid disclosed by the invention has a good dissolving effect on fibrin in thrombus formation, is relatively high in blood-brain barrier transmittance, has thrombus dissolving and antithrombotic effects, and can be used for preparing medicines for treating thrombotic diseases. The syringic acid can be processed into oral preparations such as tablets, capsules, granules, dripping pills and other common preparations or sustained release preparations, injection preparations such as injection freeze-dried powder injections, and external preparations such as ointments or emulsifiable paste according to a conventional production process of pharmaceutics, and is used for treating thrombotic diseases, especially cerebral thrombosis diseases.
Owner:SHANDONG UNIV

Traditional Chinese medicine composition for treating cerebral thrombosis precursor and later rehabilitation

The invention discloses a traditional Chinese medicine composition for treating cerebral thrombosis precursor and later rehabilitation. The traditional Chinese medicine composition is prepared from radix salviae miltiorrhizae, rhizoma atractylodis macrocephalae fried with soil, pericarpium citri reticulatae, fried malt, fructus crataegi, fried fructus aurantii immaturus, mulberries and semen cassiae. The medicine is prepared from the following raw materials in parts by weight: 7-15 parts of radix salviae miltiorrhizae, 6-15 parts of rhizoma atractylodis macrocephalae fried with soil, 6-12 parts of pericarpium citri reticulatae, 5-10 parts of fried malt, 12-20 parts of fructus crataegi, 18-25 parts of fried fructus aurantii immaturus, 5-16 parts of mulberries and 10-30 parts of semen cassiae. The traditional Chinese medicine composition can effectively improve cerebral thrombosis precursor symptoms and promote later rehabilitation, is safe and free of side effects, can be prepared into various dosage forms for clinical treatment, and has a good application prospect.
Owner:靳佳朋

Antioxidant oligopeptide from tuna bone and preparation method thereof

The present application belongs to the technical field of bioengineering, and particularly relates to a tuna fish bone antioxidant oligopeptide and a preparation method thereof.The tuna fish bone antioxidant oligopeptide has good scavenging activity, and has good thermal stability and digestion resistance; the mechanism of action is to promote the release of nitric oxide (NO), improve the levels of superoxide dismutase (SOD), glutathione peroxidase (GSH-PX), catalase (CAT) and total antioxidant capacity (T-AOC), and reduce the levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH); JQYG-1 can protect HUVEC cells from oxidative damage induced by hydrogen peroxide; JQYG-1 can exert an antioxidant effect and protect vascular endothelial cells, and can provide a candidate drug for the prevention and treatment of cardiovascular and cerebrovascular diseases such as hypertension, coronary heart disease, cerebral thrombosis, myocardial infarction, atherosclerosis and heart failure.
Owner:ZHEJIANG OCEAN UNIV

A traditional Chinese medicine composition for the recovery period of cerebral thrombosis

This invention discloses two traditional Chinese medicine compositions, namely, Composition I and Composition II, for use in the recovery period of cerebral thrombosis, and their medicinal uses. Composition I comprises 400-700 parts by weight of Astragalus membranaceus, 200-400 parts by weight of Panax notoginseng, 100-350 parts by weight of Hirudo medicinalis, and 1-10 parts by weight of Borneol. Composition II comprises 50-120 parts by weight of Astragalus membranaceus extract, 20-40 parts by weight of total Panax notoginseng saponins, 20-50 parts by weight of Hirudo medicinalis extract, and 1-10 parts by weight of Borneol. This invention also provides a drug comprising Composition I or Composition II, its preparation method, and its medicinal uses.
Owner:HARBIN ZHENBAO PHARMA

Traditional Chinese medicine preparation for treating or improving cerebral thrombosis

The invention provides a traditional Chinese medicine preparation for treating or improving cerebral thrombosis, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from lignum dalbergiae odoriferae, herba siegesbeckiae, rhodiola rosea, campsis grandiflora, radix rehmanniae praeparata, radix angelicae lateralis preparata, radix sophorae flavescentis, radix curcumae, peach kernels, dragon's blood, schizonepeta spike, radix ophiopogonis and liquorice, and has the effects of promoting blood circulation to remove blood stasis, activating meridians to stop pain, nourishing yin and clearing heat. The traditional Chinese medicine preparation has a good protection effect on experimental cerebral thrombosis mice, can well inhibit formation of cerebral thrombosis of cerebral thrombosis model rats, alleviate encephaledema conditions, effectively reduce platelet aggregation conditions, improve blood coagulation functions and alleviate cerebral thrombosis symptoms, and has a good treatment effect on the cerebral thrombosis model rats. When the traditional Chinese medicine preparation is used for treating cerebral thrombosis, the total effective rate of treatment can be remarkably increased, and the traditional Chinese medicine preparation has more advantages on improvement of nerve injury of a patient, improvement of ADL score and improvement of the blood coagulation function of the patient. The traditional Chinese medicine preparation provided by the invention has targeted treatment and improvement effects on cerebral thrombosis.
Owner:HENAN UNIV OF CHINESE MEDICINE

Preparation process for targeted therapy of various cancers and various hyperplasia heart and cerebral thrombosis diseases by light-activated methylene blue riboflavin

The invention relates to a preparation process for targeted therapy of various cancers and various hyperplasia heart and cerebral thrombosis diseases by light-activated methylene blue riboflavin. The death rate of cancer patients is about 80%, heart and cerebral thrombosis severely endangers life, and the occurrence rate of hyperplasia diseases of old people is more than 75%. The key point is that the methylene blue can dye the cells, but after the cells are colored, normal cells can decolor the methylene blue, and cancer cell hyperplasia cells and thrombus cells lose the capability of decoloring the methylene blue. The key point is that methylene blue is a molecule with positive charges and can be embedded into DNA and RNA of cancer cell hyperplasia cells and thrombus cells to prevent replication after light activation. Light-activated riboflavin can promote apoptosis of tumor cells to achieve targeted therapy, and primary observation shows that 120 mg of light-activated methylene blue each time, and the light-activated methylene blue has a targeted therapy effect on cerebral infarction, cerebral thrombosis and prostatic hyperplasia once every two days. The light-activated methylene blue riboflavin initiates a new field of targeted therapy of various cancers and various hyperplastic heart and cerebral thrombosis diseases. The preparation process comprises a preparation process of photo-activated methylene blue riboflavin and capsules.
Owner:TUXING (XIAN) PREPARATION EQUIPMENT MANUFACTURING CO LTD

Medicine formula for conditioning in-vivo circulation system and preparation process of medicine formula

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a circulation system in a body and a preparation process of the medicine formula. The invention relates to a medicine formula for conditioning in-vivo circulation system and a preparation process thereof, the medicine formula comprises a main material and an auxiliary material, and is characterized in that the main material is prepared by mixing the following raw materials by weight: 16-22g of salvia miltiorrhiza, 8-12g of astragalus membranaceus, 1-5g of pseudo-ginseng powder, 18-22g of fried spina date seed, 6-15g of ginseng, 6-12g of borneol, 18-24g of folium artemisiae argyi and 8-14g of borneol; the auxiliary material is prepared by mixing the following raw materials by weight: 10-20 g of poria cocos, 8-15 g of bighead atractylodes rhizome, 10-15 g of cassia twig, 20-25 g of dried ginger, 13-26 g of cornu cervi pantotrichum, 5-12 g of herba epimedii, 11-22 g of rhizoma polygonati, 18-28 g of codonopsis pilosula, 17-25 g of angelica sinensis and 15-30 g of chrysanthemum. The formula has the beneficial effects that the formula is scientific in preparation, balanced in nutrition and proper in proportion, has the effects of balancing yin and yang, coordinating internal organs, removing blood stasis and dissipating binds and the like, and can prevent and condition cardiovascular and cerebrovascular diseases, cerebral thrombosis, hypertension, coronary heart disease, heart failure, arrhythmia, rheumatic heart disease, palpitation, chest pain, headache, hemiplegia of half limbs, cerebral infarction and other diseases.
Owner:YIWUTANG HEALTH TECHNOLOGY (XIAN) CO LTD

Plant extract composition and application thereof

ActiveCN117731721BBlood disorderFood scienceBiotechnologyCerebral thrombosis
The present application relates to the field of biomedicine technology, and more particularly to a plant extract composition and its application. The plant extract composition comprises a water-soluble tomato concentrate and an Ampelopsis grossularis extract. Compared to conventional technologies, the beneficial effects of the embodiments of the present application include: the plant extract composition comprising a water-soluble tomato concentrate and an Ampelopsis grossularis extract provided in the embodiments of the present application has a synergistic effect in improving blood flow and / or inhibiting platelet aggregation, and preventing and treating cerebral thrombosis. The combined use of the water-soluble tomato concentrate and Ampelopsis grossularis extract significantly improves the effect compared to the use of a single extract, greatly reduces the cost, and has excellent application prospects.
Owner:BY HEALTH CO LTD

Ganoderma lucidum oral liquid containing bamboo leaf flavone and red yeast rice

The invention discloses ganoderma lucidum oral liquid containing bamboo leaf flavone and red yeast rice, and relates to the technical field of oral liquid preparation. The health-care food is prepared from the following raw materials in parts by mass: 850-950 parts of ganoderma lucidum, 95-105 parts of red yeast rice, 350-450 parts of bamboo leaf flavone and a proper amount of traditional Chinese medicine auxiliary material powder, the preparation process comprises the following steps: S1, a cleaning procedure: cleaning the ganoderma lucidum for 20 minutes to remove impurities, microorganisms and the like attached to the surface of the ganoderma lucidum so as to create a clean environment for subsequent fermentation; and S2, a ganoderma lucidum fermentation process: under the proper conditions that the temperature is 27-32 DEG C, the relative humidity is 60% and the pH value is 7.2. The ganoderma lucidum is used as a main raw material and matched with the bamboo leaf flavone, the red yeast rice and various traditional Chinese medicine auxiliary materials, so that the nutritional value of the product is greatly improved, and the product has various functions of reducing blood sugar, invigorating the kidney and strengthening Yang, reducing blood pressure, reducing blood fat, resisting aging, calming the heart and tranquilizing the mind, reducing side effects after tumor chemotherapy, promoting blood circulation to remove blood stasis, preventing cerebral thrombosis, invigorating spleen to promote digestion and the like.
Owner:HUBEI TAIZHIYUAN HEALTH IND DEVELOPMENT CO LTD

Preparation and application of aggregation-induced emission type photosensitizer with dihydrodibenzophenazine structure

The invention provides an aggregation-induced emission type photosensitizer with a dihydrodibenzophenazine structure as well as a preparation method and application of the aggregation-induced emission type photosensitizer with the dihydrodibenzophenazine structure, and the aggregation-induced emission type photosensitizer with the dihydrodibenzophenazine structure is obtained by connecting an aggregation-induced emission element with multiple rotors to a framework of a vibration-induced emission dihydrodibenzophenazine derivative. The photosensitizer with the dihydrodibenzophenazine structure integrates the advantages of aggregation-induced emission and vibration-induced emission, and can be applied to fluorescence imaging of biological tissues; the photosensitizer with the dihydrodibenzophenazine structure has viscosity responsiveness and photosensitivity, so that the photosensitizer with the dihydrodibenzophenazine structure can be applied to blood viscosity detection, thrombus imaging and tumor light diagnosis and treatment, and particularly, the photosensitizer with the dihydrodibenzophenazine structure has good performance in blood viscosity detection, thrombus, particularly in-vivo imaging of cerebral thrombosis and tumor light diagnosis and treatment.
Owner:EAST CHINA UNIV OF SCI & TECH

A traditional Chinese medicine composition, a preparation method and an oral preparation

This invention relates to the field of traditional Chinese medicine (TCM) technology, and discloses a TCM composition, preparation method, and oral formulation for treating cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type. The TCM composition is made from kudzu root, astragalus root, notoginseng, safflower, chuanxiong rhizome, hawthorn, angelica root, polygonum cuspidatum, licorice root, and salvia miltiorrhiza in specific weight parts. A preferred ratio is 60 parts kudzu root, 60 parts astragalus root, 25 parts notoginseng, 30 parts safflower, 25 parts chuanxiong rhizome, 30 parts hawthorn, 25 parts angelica root, 25 parts polygonum cuspidatum, 10 parts licorice root, and 26 parts salvia miltiorrhiza. It can be used for coronary heart disease, cerebral arteriosclerosis, cerebral thrombosis, hyperlipidemia, or sequelae of cerebral infarction. In preparation, the medicinal materials are cleaned, dried, mixed, and pulverized into a fine powder, passed through a 120-180 mesh sieve, and then formed into water pills using water as a binder. After drying and packaging, the product is obtained. This invention has a scientific formulation and precise proportions, making it suitable for the long-term prevention and treatment of cardiovascular and cerebrovascular diseases of the Qi deficiency and blood stasis type.
Owner:YONGNINGTANG HEALTH IND (SHENZHEN) CO LTD

Medicine for treating cerebral thrombosis, cerebral thrombosis precursor and cerebral thrombosis sequelae

PendingCN121422142AAntinoxious agentsBlood disorderSequelaSiegesbeckia orientalis
The invention relates to a medicine for treating cerebral thrombosis, cerebral thrombosis precursor and cerebral thrombosis sequelae. Comprising the following raw materials in parts by weight: 15-30 parts of astragalus membranaceus, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae rubra, 10-20 parts of gastrodia elata, 2-5 parts of scorpion, 10-20 parts of pseudo-ginseng, 10-20 parts of rhizoma corydalis, 10-20 parts of radix clematidis, 10-20 parts of earthworm, 10-20 parts of honeysuckle stem, 10-20 parts of ginkgo leaf, 1-3 parts of centipede, 10-20 parts of cassia twig, 2-5 parts of leech and 10-20 parts of herba siegesbeckiae. The traditional Chinese medicine is orally taken and externally applied, and has the effects of dispersing blood stasis, relieving spasm, activating blood, relieving pain, tonifying qi and nourishing blood.
Owner:高中香

Cerebral thrombus extraction device

PendingCN122272110ACerebral thrombosisCerebral Thrombus
This invention discloses a cerebral thrombosis removal device, comprising an outer cannula, a first catheter, a thrombus fragmentation structure, and an artificial blood vessel. The proximal and distal ends of the outer cannula respectively form a first inlet and a first outlet communicating with a first channel. The first catheter is disposed within the first channel. The thrombus fragmentation structure includes a second catheter and a fragmentation section located distal to the second catheter. The second catheter is movably disposed within the first catheter and can extend from the first outlet to fragment the thrombus at the target lesion site. An aspiration channel is formed inside the second catheter, with its distal opening located near the fragmentation section for aspirating the fragmented thrombus fragments. The artificial blood vessel includes a third catheter, the distal end of which is used to cross the thrombus at the target lesion site to reach a distal blood vessel and deliver blood to temporarily relieve ischemia. This invention's cerebral thrombosis removal device can extend the safe surgical time window.
Owner:SOUTHERN UNIV OF SCI & TECH HOSPITAL (XILI PEOPLES HOSPITAL NANSHAN DISTRICT SHENZHEN)

Amide alkyl mercaptan ketal compound as well as preparation method and application thereof

The invention discloses an amide alkyl thiol ketal compound (I), pharmaceutically acceptable salts thereof, a preparation method of the amide alkyl thiol ketal compound, a pharmaceutical composition of the amide alkyl thiol ketal compound, and application of the amide alkyl thiol ketal compound in preparation of drugs for treating and / or preventing nervous system related diseases and myocardial ischemia related diseases. Comprising but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, cerebral arterial thrombosis, hemorrhagic cerebral thrombosis, nerve injury caused by cerebral trauma, myocardial ischemic injury and other diseases;
Owner:SICHUAN UNIV

Application of novel glycyrrhizol in preparation of product for preventing or treating ischemic encephalopathy

PendingCN121313632AOrganic active ingredientsBlood disorderThrombusIschaemic encephalopathy
The invention belongs to the technical field of medicines, and particularly relates to application of novel glycyrrhizol in preparation of products for preventing or treating ischemic encephalopathy, and the ischemic encephalopathy comprises cerebral thrombosis, cerebrovascular stenosis / occlusion and cerebral atherosclerosis. According to the application disclosed by the invention, the novel glycyrrhizol is used for treating the ischemic encephalopathy for the first time, and experiments show that the novel glycyrrhizol has a remarkable treatment effect on the ischemic encephalopathy, can be used for obviously improving behavioral scores, cerebral thrombosis and vascular diameter conditions after ischemia and reducing the volume of cerebral infarction, and has a good treatment effect on cerebral thrombosis and middle artery embolism. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.
Owner:QINGDAO UNIV

Neural stem cells for treating cerebrovascular and cerebral thrombosis diseases and culture method

PendingCN121022746ACulture processNervous system cellsCerebral thrombosisMedicine
The invention belongs to the technical field of neural stem cell culture, and particularly relates to neural stem cells for treating cerebrovascular and cerebral thrombosis diseases and a culture method. The neural stem cell culture medium for treating cerebrovascular and cerebral thrombosis diseases comprises: (1) a basic culture medium; (2) cecropin, wherein the concentration of the cecropin in the basic culture medium is 5-10 [mu] g / mL; (3) a plant extract, wherein the concentration of the plant extract in the basic culture medium is 10-20 [mu] g / mL; and (4) bletilla striata exosome, wherein the concentration of the bletilla striata exosome in the basal culture medium is 10-20 [mu] g / mL. According to the culture medium, under the condition that the basic culture medium is added, the cecropin, the plant extract and the bletilla striata exosome are additionally added, through the synergistic effect of the cecropin, the plant extract and the bletilla striata exosome, the value-added stability in the neural stem cell culture process is facilitated, meanwhile, the neural stem cells can keep the cell characteristics of the neural stem cells, and the culture efficiency is improved. The preparation efficiency of the neural stem cells is improved.
Owner:GUANGDONG CELL BIOTECHNOLOGY CO LTD

Leonurus phenolic acid extract with thrombolysis effect as well as preparation method and application thereof

The invention provides a motherwort phenolic acid extract with a thrombolysis effect as well as a preparation method and application of the motherwort phenolic acid extract. The method provided by the invention can effectively extract the effective part with fibrinolysis effect in motherwort; the herba leonuri phenolic acid extract is mainly prepared from vanillic acid, syringic acid, trans-ferulic acid, cis-ferulic acid and 3, 4, 5-trimethyl gallic acid, and the total content of the herba leonuri phenolic acid extract is not lower than 70%. The herba leonuri phenolic acid extract has a good dissolving effect on fibrin in thrombosis, has thrombus dissolving and antithrombotic effects, and can be processed into various common preparations or sustained release preparations such as oral preparations such as tablets, capsules, granules and dropping pills according to a conventional production process of pharmaceutics; injection preparations such as injection freeze-dried powder injections and external preparations such as ointment and emulsifiable paste are used for treating thrombotic diseases (including cerebral thrombosis and subcutaneous blood stasis).
Owner:SHANDONG UNIV

Cerebral thrombosis resection device with protection function

ActiveCN222942413UExcision instrumentsCerebral thrombosisCerebral Thrombus
The utility model discloses a cerebral thrombosis resection device with a protection function, which relates to the technical field of medical instruments, comprises a sleeve, and is characterized in that a resection mechanism is arranged at one end of the sleeve, and a front-end guide wire for penetrating thrombus is arranged on one side, opposite to the sleeve, of the resection mechanism; the cutting mechanism comprises a fixing ring, the fixing ring is fixedly connected with the surface of one side of the front-end guide wire, a penetrating hole convenient to joint with the surface of one side of the sleeve is formed in the center of the fixing ring, and the fixing ring is fixedly connected with the surface of one side of the sleeve. The side, opposite to the front-end guide wire, of the fixing ring is fixedly connected with a woven net, and a plurality of net basket bundles are arranged on one side of the woven net. In the scheme, by arranging the excision mechanism and the control assembly, the thrombus fixing effect of the excision device can be enhanced in the using process, thrombus movement can be reduced in the capturing process, and the thrombus capturing efficiency is improved. And the capturing efficiency and success rate are improved.
Owner:CHENGDU WEISTEKE MEDICAL EQUIPMENT TECHNOLOGY CO LTD